Apogee Therapeutics, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-14$82.43 RISE2026-03-20$66.04 PEAK2026-04-17$92.20 93d | -19.9% 65d | Missed | Missed | — | — | +39.6% 28d | Missed |
DROP2026-01-14$82.43 RISE2026-02-09$62.13 PEAK2026-04-17$92.20 93d | -24.6% 26d | Missed | Missed | — | — | +48.4% 67d | Missed |
DROP2026-01-14$82.43 RISE2026-02-05$62.13 PEAK2026-04-17$92.20 93d | -24.6% 22d | Missed | Missed | — | — | +48.4% 71d | Missed |
DROP2025-07-03$47.46 RISE2025-08-11$34.65 PEAK2025-10-20$56.94 109d | -27.0% 39d | Missed | Missed | — | — | +64.3% 70d | Missed |
DROP2024-12-04$52.02 RISE2025-04-08$28.79 PEAK2025-07-03$47.46 211d | -44.7% 125d | Missed | Missed | — | — | +64.8% 86d | Missed |
DROP2024-11-08$61.12 RISE2025-03-04$30.37 PEAK2025-03-24$40.84 136d | -50.3% 116d | Missed | Missed | — | — | +34.5% 20d | Missed |
DROP2024-11-08$61.12 RISE2024-11-21$42.86 PEAK2024-12-04$52.02 26d | -29.9% 13d | Missed | Missed | — | — | +21.4% 13d | Missed |
DROP2024-04-01$65.05 RISE2024-08-08$40.36 PEAK2024-09-24$59.92 176d | -38.0% 129d | Missed | Missed | — | — | +48.5% 47d | Missed |
DROP2024-03-13$69.80 RISE2024-06-18$36.37 PEAK2024-09-13$51.38 184d | -47.9% 97d | Missed | Missed | — | — | +41.3% 87d | Missed |
DROP2024-03-13$69.80 RISE2024-04-25$45.86 PEAK2024-05-06$54.31 54d | -34.3% 43d | Missed | Missed | — | — | +18.4% 11d | Missed |
DROP2023-09-01$24.71 RISE2023-10-26$15.00 PEAK2024-01-24$34.90 145d | -39.3% 55d | Missed | Missed | — | — | +132.7% 90d | Missed |
Apogee Enterprises (NASDAQ:APOG) has entered a strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion in non-dilutive capital, combining up to $800 million in synthetic royalty financing with as much as $500 million in senior corporate debt, giving the immunology...
Apogee Therapeutics, Inc. rated Buy: zumilokibart Phase 2b AD results, 2â4 doses/yr, Blackstone $1.3B funding; fair value $82.97âread now. Click for an APGE update.
Apogee Therapeutics revealed mixed results for its experimental eczema treatment Wednesday, and the stock dropped.
Apogee gains financing to advance zumilokibart after mid-stage atopic dermatitis trial results.
Truist Securities analyst Danielle Brill maintains Apogee Therapeutics (NASDAQ:APGE) with a Hold and lowers the price target from $83 to $81.
May 27 (Reuters) - Apogee Therapeutics said on Wednesday it secured a financing deal with Blackstone Life Sciences worth up to $1.3 billion to support late-stage development and potential
BTIG analyst Julian Harrison reiterates Apogee Therapeutics (NASDAQ:APGE) with a Buy and maintains $137 price target.
Shares of Apogee Therapeutics (NASDAQ:APOG) climbed roughly 16% in premarket trading on Wednesday after the biotechnology company announced a $1. 3 billion financing agreement with Blackstone Life Sciences to support the development and commercial launch of zumilokibart, its treatment candidate for atopic dermatitis.
Apogee Therapeutics (APGE) entered a strategic financing collaboration with Blackstone (BX) Life Sci
Apogee shares fell after announcing a $1.3 billion Blackstone financing deal alongside positive Phase 2 eczema drug results.
Wedbush analyst David Nierengarten maintains Apogee Therapeutics (NASDAQ:APGE) with a Outperform and raises the price target from $120 to $135.
APEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zumilokibart planned to advance into Phase 3 trials in moderate-to-severe atopic dermatitis (AD) in 2H 2026Zumilokibart was
Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and access of up to $500 million in senior corporate debtCombined with company's current total cash of $1.3 billion,
Apogee Therapeutics, Inc. is rated a Hold, driven by promising data for the lead asset zumilokibart in atopic dermatitis. Read more on APGE stock here.
Apogee Therapeutics beats Q1 estimates with strong cash runway into 2029, reports positive zumilokibart data in atopic dermatitis and plans Phase 3 initiation in 2026.
Apogee Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported net loss was USD 74.11 million compared to USD 55.34 million...
Apogee Therapeutics (NASDAQ:APGE) reported quarterly losses of $(1.06) per share which beat the analyst consensus estimate of $(1.08) by 1.85 percent. This is a 11.58 percent decrease over losses of $(0.95) per share
Zumilokibart advancing across multiple indications, with Phase 3 initiation in atopic dermatitis expected later this year:- APEX Phase 2 Part A 52-week data demonstrated durable maintenance and...
Rothschild & Co analyst Qize Ding initiates coverage on Apogee Therapeutics (NASDAQ:APGE) with a Buy rating and announces Price Target of $140.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| APGE | +1.72% | +15.83% | +8.82% | +124.18% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -1.25% | +21.54% | +12.27% | +111.49% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 9.26M | $779.61M | 0.04% | Added+12.6% | 2026-03-31 |
| Wellington | fundamental | 4.38M | $368.30M | 0.07% | Trimmed-7.8% | 2026-03-31 |
| StateStreet | passive | 2.16M | $182.06M | 0.01% | Added+28.0% | 2026-03-31 |
| TwoSigma | quant | 281.4K | $23.68M | 0.02% | Added+167.4% | 2026-03-31 |
| DEShaw | quant | 58.8K | $4.95M | 0.00% | Trimmed-7.0% | 2026-03-31 |
| TRowePrice | fundamental | 1.14M | $96.22K | 0.01% | Trimmed-7.6% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-10upcoming | -0.89 | — | — |
| 2026-05-11 | -1.13 | -1.06 | +6.30% |
| 2026-03-02 | -1.04 | -1.03 | +0.73% |
| 2025-11-10 | -1.15 | -1.11 | +3.35% |
| 2025-08-11 | -1.05 | -1.13 | -7.93% |
| 2025-05-12 | -1.19 | -0.95 | +20.19% |
| 2025-03-03 | -1.07 | -1.20 | -11.89% |
| 2024-11-12 | -0.74 | -0.86 | -16.22% |
| 2024-08-12 | -0.55 | -0.60 | -9.09% |
| 2024-05-13 | -0.65 | -0.64 | +1.54% |
| 2024-03-05 | -0.55 | -0.32 | +41.82% |
| 2023-11-13 | -0.42 | -0.51 | -20.00% |
| 2023-08-28 | -2.31 | -3.78 | -63.28% |